Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03772665 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Emixustat in Stargardt Disease
A Phase 3 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 3
- Development phase
- 194
- Enrollment target
NCT03772665 is a Phase 3 study that has completed, run by Kubota Vision. The registered enrollment target is 194 participants.
The verdict
NCT03772665, a Phase 3 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 194 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD
Interventions
- DRUG Placebo
- DRUG Emixustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2022-06-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03772665
The ClinicalTrials.gov registry entry for NCT03772665 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kubota Vision, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03772665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03772665 about?
NCT03772665 is a clinical study titled "Safety and Efficacy of Emixustat in Stargardt Disease". The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD
What is the current status of trial NCT03772665?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 194 participants. The study started on 2019-01-07. Estimated completion is 2022-06-23.
What interventions are being tested in trial NCT03772665?
The interventions under investigation include: Placebo (DRUG), Emixustat (DRUG).
Who is sponsoring clinical trial NCT03772665?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.